Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity

eLife

Volumn 5, Issue MAY2016, 2016, Pages

  Shirakawa, Kotaro ^a,b,c   Wang, Lan ^d,e   Man, Na ^d,e   Maksimoska, Jasna ^f,g   Sorum, Alexander W ^h   Lim, Hyung W ^a,b   Lee, Intelly S ^a,b   Shimazu, Tadahiro ^a,b   Newman, John C ^a,b   Schröder, Sebastian ^a,b   Ott, Melanie ^a,b   Marmorstein, Ronen ^f,g   Meier, Jordan ^h   Nimer, Stephen ^d,e   Verdin, Eric ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KYOTO UNIVERSITY   (Japan)

^d UNIVERSITY OF MIAMI   (United States)

^e UNIVERSITY OF MIAMI   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g Abramson Family Cancer Research Institute   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COENZYME A; DIFLUNISAL; HISTONE ACETYLTRANSFERASE GCN5; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE INHIBITOR; HYBRID PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; RECOMBINANT PROTEIN; SALICYLATE SODIUM; SALICYLIC ACID; ACETYL COENZYME A; AML1-ETO FUSION PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; ONCOPROTEIN; P300-CBP-ASSOCIATED FACTOR; PROTEIN BINDING; PROTEIN CBFA2T1; TRANSCRIPTION FACTOR RUNX1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTORADIOGRAPHY; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FLOW CYTOMETRY; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THERMOSTABILITY; WESTERN BLOTTING; X RAY CRYSTALLOGRAPHY; ACETYLATION; ACUTE MYELOID LEUKEMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVE SITE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; LEUKOCYTE; METABOLISM; PATHOLOGY; SCID MOUSE; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ACETYL COENZYME A; ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; CATALYTIC DOMAIN; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DIFLUNISAL; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, LEUKEMIC; HEK293 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES; MICE; MICE, SCID; ONCOGENE PROTEINS, FUSION; P300-CBP TRANSCRIPTION FACTORS; PROTEIN BINDING; RUNX1 TRANSLOCATION PARTNER 1 PROTEIN; SALICYLIC ACID; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84979496867     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.11156     Document Type: Article

References (48)

1. Ait-Si-Ali S, Polesskaya A, Filleur S, Ferreira R, Duquet A, Robin P, Vervish A, Trouche D, Cabon F, Harel-Bellan A. 2000. CBP/p300 histone acetyl-transferase activity is important for the G1/S transition. Oncogene 19:2430-2437. doi: 10.1038/sj.onc.1203562
2. Bai Y, Soda Y, Izawa K, Tanabe T, Kang X, Tojo A, Hoshino H, Miyoshi H, Asano S, Tani K. 2003. Effective transduction and stable transgene expression in human blood cells by a third-generation lentiviral vector. Gene Therapy 10:1446-1457. doi: 10.1038/sj.gt.3302026
3. Balasubramanyam K, Swaminathan V, Ranganathan A, Kundu TK. 2003. Small molecule modulators of histone acetyltransferase p300. The Journal of Biological Chemistry 278:19134-19140. doi: 10.1074/jbc.M301580200
4. Becker H, Pfeifer D, Afonso JD, Nimer SD, Veelken H, Schwabe M, Lübbert M. 2008. Two cell lines of t(8;21)acute myeloid leukemia with activating KIT exon 17 mutation: models for the ‘second hit’ hypothesis. Leukemia 22:1792-1794. doi: 10.1038/leu.2008.61
5. Bordoli L, Netsch M, Lüthi U, Lutz W, Eckner R. 2001. Plant orthologs of p300/CBP: conservation of a core domain in metazoan p300/CBP acetyltransferase-related proteins. Nucleic Acids Research 29:589-597. doi: 10. 1093/nar/29.3.589
6. Boyes J, Byfield P, Nakatani Y, Ogryzko V. 1998. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 396:594-598. doi: 10.1038/25166
7. Chen J, Li Q. 2011. Life and death of transcriptional co-activator p300. Epigenetics 6:957-961. doi: 10.4161/epi. 6.8.16065
8. Chen LF, Fischle W, Verdin E, Greene WC. 2001. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293:1653-1657. doi: 10.1126/science.1062374
9. Chen LF, Mu Y, Greene WC. 2002. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. The EMBO Journal 21:6539-6548. doi: 10.1093/emboj/cdf660
10. Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, Mann M. 2011. Andromeda: a peptide search engine integrated into the MaxQuant environment. Journal of Proteome Research 10:1794-1805. doi: 10.1021/pr101065j
11. Cromlish WA, Kennedy BP. 1996. Selective inhibition of cyclooxygenase-1 and -2 using intact insect cell assays. Biochemical Pharmacology 52:1777-1785. doi: 10.1016/S0006-2952(96)00599-0
12. Das C, Lucia MS, Hansen KC, Tyler JK. 2009. CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature 459:113-117. doi: 10.1038/nature07861
13. Dekker FJ, Haisma HJ. 2009. Histone acetyl transferases as emerging drug targets. Drug Discovery Today 14:942-948. doi: 10.1016/j.drudis.2009.06.008
14. Donath MY, Shoelson SE. 2011. Type 2 diabetes as an inflammatory disease. Nature Reviews. Immunology 11:98-107. doi: 10.1038/nri2925
15. Fanslau C, Pedicord D, Nagulapalli S, Gray H, Pang S, Jayaraman L, Lippy J, Blat Y. 2010. An electrophoretic mobility shift assay for the identification and kinetic analysis of acetyl transferase inhibitors. Analytical Biochemistry 402:65-68. doi: 10.1016/j.ab.2010.03.025
16. Fu ZQ, Yan S, Saleh A, Wang W, Ruble J, Oka N, Mohan R, Spoel SH, Tada Y, Zheng N, Dong X. 2012. NPR3 and NPR4 are receptors for the immune signal salicylic acid in plants. Nature 486:228-232. doi: 10.1038/nature11162
17. Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE, TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team. 2010. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Annals of Internal Medicine 152:346-357. doi: 10.7326/0003-4819-152-6-201003160-00004
18. Goldfine AB, Conlin PR, Halperin F, Koska J, Permana P, Schwenke D, Shoelson SE, Reaven PD. 2013. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia 56:714-723. doi: 10.1007/s00125-012-2819-3
19. Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ, Peggie MW, Zibrova D, Green KA, Mustard KJ, Kemp BE, Sakamoto K, Steinberg GR, Hardie DG. 2012. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 336:918-922. doi: 10.1126/science.1215327
20. Iyer NG, Xian J, Chin SF, Bannister AJ, Daigo Y, Aparicio S, Kouzarides T, Caldas C. 2007. p300 is required for orderly G1/S transition in human cancer cells. Oncogene 26:21-29. doi: 10.1038/sj.onc.1209771
21. Knights KM, Sykes MJ, Miners JO. 2007. Amino acid conjugation: contribution to the metabolism and toxicity of xenobiotic carboxylic acids. Expert Opinion on Drug Metabolism & Toxicology 3:159-168. doi: 10.1517/17425255.3.2.159
22. Kopp E, Ghosh S. 1994. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265:956-959. doi: 10. 1126/science.8052854
23. Kouzarides T. 2007. Chromatin modifications and their function. Cell 128:693-705. doi: 10.1016/j.cell.2007.02. 005
24. Maksimoska J, Segura-Peña D, Cole PA, Marmorstein R. 2014. Structure of the p300 histone acetyltransferase bound to acetyl-coenzyme A and its analogues. Biochemistry 53:3415-3422. doi: 10.1021/bi500380f
25. Mano Y, Usui T, Kamimura H. 2006. In vitro drug interaction between diflunisal and indomethacin via glucuronidation in humans. Biopharmaceutics & Drug Disposition 27:267-273. doi: 10.1002/bdd.507
26. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. 1993. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proceedings of the National Academy of Sciences of the United States of America 90:11693-11697. doi: 10.1073/pnas.90.24.11693
27. Montgomery DC, Sorum AW, Meier JL. 2014. Chemoproteomic profiling of lysine acetyltransferases highlights an expanded landscape of catalytic acetylation. Journal of the American Chemical Society 136:8669-8676. doi:10.1021/ja502372j
28. Nuernberg B, Koehler G, Brune K. 1991. Pharmacokinetics of diflunisal in patients. Clinical Pharmacokinetics 20:81-89. doi: 10.2165/00003088-199120010-00006
29. Oeth P, Mackman N. 1995. Salicylates inhibit lipopolysaccharide-induced transcriptional activation of the tissue factor gene in human monocytic cells. Blood 86:4144-4152.
30. Padmakumar R, Padmakumar R, Banerjee R. 1997. Large-scale synthesis of coenzyme A esters. Methods in Enzymology 279:220-224. doi: 10.1016/S0076-6879(97)79026-8
31. Patrignani P, Panara MR, Sciulli MG, Santini G, Renda G, Patrono C. 1997. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. Journal of Physiology and Pharmacology 48:623-631.
32. Pierce JW, Read MA, Ding H, Luscinskas FW, Collins T. 1996. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. Journal of Immunology 156:3961-3969.
33. Schiltz RL, Mizzen CA, Vassilev A, Cook RG, Allis CD, Nakatani Y. 1999. Overlapping but distinct patterns of histone acetylation by the human coactivators p300 and PCAF within nucleosomal substrates. The Journal of Biological Chemistry 274:1189-1192. doi: 10.1074/jbc.274.3.1189
34. Schwenger P, Skolnik EY, Vilcek J. 1996. Inhibition of tumor necrosis factor-induced p42/p44 mitogen-activated protein kinase activation by sodium salicylate. The Journal of Biological Chemistry 271:8089-8094 doi: 10. 1074/jbc.271.14.8089.
35. Schwenger P, Bellosta P, Vietor I, Basilico C, Skolnik EY, Vilcek J. 1997. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proceedings of the National Academy of Sciences of the United States of America 94:2869-2873. doi: 10.1073/pnas.94.7.2869
36. Schwenger P, Alpert D, Skolnik EY, Vilcek J. 1999. Cell-type-specific activation of c-Jun N-terminal kinase by salicylates. Journal of Cellular Physiology 179:109-114. doi: 10.1002/(SICI)1097-4652(199904)179:1<109::AID-JCP13>3.0.CO;2-W
37. Sung B, Pandey MK, Ahn KS, Yi T, Chaturvedi MM, Liu M, Aggarwal BB. 2008. Anacardic acid (6-nonadecyl salicylic acid), an inhibitor of histone acetyltransferase, suppresses expression of nuclear factor-kappaB-regulated gene products involved in cell survival, proliferation, invasion, and inflammation through inhibition of the inhibitory subunit of nuclear factor-kappaBalpha kinase, leading to potentiation of apoptosis. Blood 111:4880-4891. doi: 10.1182/blood-2007-10-117994
38. Suzuki T, Kimura A, Nagai R, Horikoshi M. 2000. Regulation of interaction of the acetyltransferase region of p300 and the DNA-binding domain of Sp1 on and through DNA binding. Genes to Cells 5:29-41. doi: 10.1046/j. 1365-2443.2000.00302.x
39. Thompson PR, Wang D, Wang L, Fulco M, Pediconi N, Zhang D, An W, Ge Q, Roeder RG, Wong J, Levrero M, Sartorelli V, Cotter RJ, Cole PA. 2004. Regulation of the p300 HAT domain via a novel activation loop. Nature Structural & Molecular Biology 11:308-315. doi: 10.1038/nsmb740
40. Vane JR. 1971. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 231:232-235. doi: 10.1038/newbio231232a0
41. Vargaftig BB. 1978. Salicylic acid fails to inhibit generation of thromboxane A2 activity in platelets after in vivo administration to the rat. The Journal of Pharmacy and Pharmacology 30:101-104. doi: 10.1111/j.2042-7158. 1978.tb13171.x
42. Wang L, Gural A, Sun XJ, Zhao X, Perna F, Huang G, Hatlen MA, Vu L, Liu F, Xu H, Asai T, Xu H, Deblasio T, Menendez S, Voza F, Jiang Y, Cole PA, Zhang J, Melnick A, Roeder RG, et al. 2011. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 333:765-769. doi: 10.1126/science. 1201662
43. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. 1999. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proceedings of the National Academy of Sciences of the United States of America 96:7563-7568. doi:10.1073/pnas.96.13.7563
44. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J. 2006. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Research 34:D668-672. doi:10.1093/nar/gkj067
45. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M. 2008. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Research 36:D901-906. doi: 10.1093/nar/gkm958
46. Xu XM, Sansores-Garcia L, Chen XM, Matijevic-Aleksic N, Du M, Wu KK. 1999. Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proceedings of the National Academy of Sciences of the United States of America 96:5292-5297. doi: 10.1073/pnas.96.9.5292
47. Yin MJ, Yamamoto Y, Gaynor RB. 1998. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I (kappa)B kinase-beta. Nature 396:77-80. doi: 10.1038/23948
48. Zhang Y, Qiu J, Wang X, Zhang Y, Xia M. 2011. AMP-activated protein kinase suppresses endothelial cell inflammation through phosphorylation of transcriptional coactivator p300. Arteriosclerosis, Thrombosis, and Vascular Biology 31:2897-2908. doi: 10.1161/ATVBAHA.111.237453